A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
Condition: B-Cell Non-Hodgkin Lymphoma Interventions: Drug: Epcoritamab; Drug: Cyclophosphamide; Drug: Rituximab; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone; Drug: Lenalidomide Sponsors: AbbVie; Genmab Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: China Health | Hodgkin's Disease | Lymphoma | Non-Hodgkin's Lymphoma | Prednisone | Research | Revlimid | Rituxan | Study